Sign In
Buy ELYM
$5.11
+0 (+0%)
At Close: Dec 31, 2024
Eliem Therapeutics (NASDAQ:ELYM) Trading Up 5.4% – Here’s What Happened
02:07am, Saturday, 27'th Dec 2025
Eliem Therapeutics, Inc. (NASDAQ: ELYM - Get Free Report)'s share price shot up 5.4% during trading on Friday. The company traded as high as $4.96 and last traded at $4.85. 323,001 shares were traded
Eliem Therapeutics (NASDAQ:ELYM) Trading Up 6.1% – Should You Buy?
02:27am, Friday, 05'th Dec 2025
Eliem Therapeutics, Inc. (NASDAQ: ELYM - Get Free Report) shares shot up 6.1% during trading on Thursday. The stock traded as high as $1.75 and last traded at $1.74. 320,070 shares were traded during
Climb Bio to Host Virtual Investor Event on October 15, 2024
10:00am, Thursday, 03'rd Oct 2024
WELLESLEY, Mass., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), announced today it will host a virtual investor day on October 15, 2024. The event will feature members of Climb Bi
Eliem Therapeutics Announces Rebranding and Corporate Name Change to Climb Bio, Inc.
09:00am, Wednesday, 02'nd Oct 2024
Name change to "Climb Bio" marks the Company's transition and focus on developing treatments for immune-mediated diseases
Eliem Therapeutics to Participate at the Stifel 2024 Virtual Immunology and Inflammation Summit
07:00am, Wednesday, 11'th Sep 2024
SEATTLE and CAMBRIDGE, United Kingdom, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), announced today members of the management team will participate at the Stifel 2024 Vi
Eliem Therapeutics Announces Additions to its Leadership Team
07:00am, Monday, 26'th Aug 2024
Brett Kaplan, M.D. appointed Chief Operating Officer Nishi Rampal, M.D.
Eliem Therapeutics Reports Second Quarter Financial Results
06:05am, Wednesday, 14'th Aug 2024
Eliem completed the acquisition of Tenet Medicines and concurrent $120 million private placement Eliem to host an Investor Day later in the year to provide an overview of budoprutug (previously referr
Eliem Therapeutics: Year End 2024 MN Data With Further Potential To Unlock Value
01:58pm, Friday, 28'th Jun 2024
Results from Eliem Therapeutics, Inc.'s phase 1b study, using TNT119 for the treatment of patients with membranous nephropathy, expected by the end of 2024. It is expected that the global membranous n
Eliem Therapeutics Announces its Addition to the Russell 2000® and Russell 3000® Indexes
07:00am, Friday, 28'th Jun 2024
SEATTLE and CAMBRIDGE, United Kingdom, June 28, 2024 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), announced today that the Company will be included in the Russell 2000® Index and the
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
04:01pm, Thursday, 27'th Jun 2024
Eliem to focus on advancing TNT119, an anti-CD19 antibody designed to treat a broad range of autoimmune diseases, including systemic lupus erythematosus, immune thrombocytopenia and membranous nephrop
PHILADELPHIA , April 15, 2024 /PRNewswire/ -- Kaskela Law LLC, announces that it is investigating Eliem Therapeutics, Inc. (NASDAQ: ELYM) ("Eliem") on behalf of the company's shareholders. The investi
ELYM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Eliem Therapeutics, Inc. Is Fair to Shareholders
08:30am, Thursday, 11'th Apr 2024
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Eliem Therapeutics, Inc. (NASDAQ: ELYM) and Tenet Medicines, Inc. is fair to Eliem shar
Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
07:00am, Thursday, 11'th Apr 2024
Transaction to add clinical-stage program directed towards treating unmet needs in autoantibody-mediated diseases Combined company expected to have approximately $210 million of cash and cash equivale
Eliem (ELYM) to Explore Strategic Options, Stock Rises 6%
08:27am, Friday, 21'st Jul 2023
Eliem (ELYM) announces its decision to halt its Kv7 development program in its quest to explore strategic alternatives. The stock of the company rises 6% in response on Thursday.
Why Is Eliem Therapeutics (ELYM) Stock Up 6% Today?
08:04am, Thursday, 20'th Jul 2023
Eliem Therapeutics (NASDAQ: ELYM ) stock is taking off on Thursday after the biotechnology company announced plans to explore strategic alternatives. Eliem Therapeutics came to this decision after co
